Cancer
Conditions
Keywords
Solid Tumors, Lymphomas
Brief summary
This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics of escalating doses of the vascular disrupting agent NPI-2358 in patients with refractory solid tumors or lymphoma. The formation of new blood vessels (angiogenesis) is an important component of tumor growth and vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues. NPI-2358 has also been seen to directly affect tumor cells.
Interventions
DRUGNPI-2358
Treatment on Days 1, 8 and 15 in a 28 day cycle
Sponsors
Nereus Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ECOG performance status ≤ 2 * Pathologically or histologically confirmed solid tumor malignancy * Patients must not be candidates for regimens known to provide clinical benefit. * All adverse events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (v. 3.0) Grade ≤ 2, except for neurological toxicity that must have resolved to Grade ≤ 1. * Adequate bone marrow reserve, hepatic and renal function * Signed informed consent
Exclusion criteria
* Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic) within 21 days prior to receipt of study medication (6 weeks for nitrosoureas or mitomycin C; 12 weeks for radioimmunotherapy). Major surgery, other than diagnostic surgery, within 6 weeks before first study drug administration. Radiotherapy within 4 weeks (some types of radiation therapy are excluded regardless of interval since treatment). * Significant cardiac history or findings * Underlying conditions or medications associated with bleeding diathesis * Disorders associated with significant vascular pathology * Lung cancer with central chest tumors * Prior treatment with vascular disruptive agents * Seizure disorder requiring anticonvulsant therapy; prior transient ischemic attack or cerebrovascular accident * Brain metastases * Severe chronic obstructive pulmonary disease (COPD) with hypoxemia * Active uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy * Known infection with human immunodeficiency virus (HIV), active hepatitis A, B, or C * Patients with a prior hypersensitivity reaction to any product containing Solutol and/or propylene glycol * Pregnant or breast-feeding women. Female patients must be postmenopausal, surgically sterile or they must agree to use acceptable methods of birth control. Female patients with childbearing potential must have a negative serum pregnancy test. Male patients must be surgically sterile or agree to use an acceptable method of contraception. * Concurrent, active second malignancy for which the patient is receiving therapy, excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | continuously |
| Tolerability | continuously |
| Maximum tolerated dose (MTD) | continuously |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics | continuously |
| Pharmacodynamics | continuously |
| Response Evaluation Criteria in Solid Tumors (RECIST) | continuously |
Countries
United States
Outcome results
None listed